Evoke Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Evoke Pharma has a total shareholder equity of $4.4M and total debt of $5.0M, which brings its debt-to-equity ratio to 114%. Its total assets and total liabilities are $14.2M and $9.8M respectively.
Key information
114.0%
Debt to equity ratio
US$5.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$11.34m |
| Equity | US$4.39m |
| Total liabilities | US$9.77m |
| Total assets | US$14.15m |
Recent financial health updates
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22
Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14Financial Position Analysis
Short Term Liabilities: EVOK's short term assets ($14.0M) exceed its short term liabilities ($9.8M).
Long Term Liabilities: EVOK has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: EVOK has more cash than its total debt.
Reducing Debt: EVOK's debt to equity ratio has increased from 0% to 114% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVOK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EVOK has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 0.8% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 23:07 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evoke Pharma, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Difei Yang | Brean Capital |
| David Buck | B. Riley Securities, Inc. |